AHA/ASA guideline recommendations for prevention of stroke

Ischemic Stroke Microchapters
Main Stroke Page
Transient ischemic attack
Hemorrhagic Stroke Page
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Stroke from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
CT
MRI
Echocardiography
Ultrasound
Other Imaging Findings
Treatment
Early Assessment
Medical Therapy
Surgery
Rehabilitation
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
AHA/ASA Guidelines for Stroke
Case Studies
Case #1
AHA/ASA guideline recommendations for prevention of stroke On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of AHA/ASA guideline recommendations for prevention of stroke All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on AHA/ASA guideline recommendations for prevention of stroke
CDC on AHA/ASA guideline recommendations for prevention of stroke
AHA/ASA guideline recommendations for prevention of stroke in the news
Blogs on AHA/ASA guideline recommendations for prevention of stroke
Directions to Hospitals Treating Stroke
Risk calculators and risk factors for AHA/ASA guideline recommendations for prevention of stroke

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];

2014 AHA/ASA Guidelines for the Primary Prevention of Stroke

Genetic Factors: Recommendations

Class III (Harm)

"1.Genetic screening to determine risk for myopathy is not recommended when initiation of statin therapy is being considered (Level of Evidence: C)"

"2. Genetic screening of the general population for the prevention of a first stroke is not recommended (Level of Evidence: C)"

"3.Screening for intracranial aneurysms in every car- rier of autosomal-dominant polycystic kidney disease or Ehlers-Danlos type IV mutations is not recommended (Level of Evidence: C)"

"4. Noninvasive screening for unruptured intracranial aneurysms in patients with no more than 1 relative with SAH or intracranial aneurysms is not recommended (Level of Evidence: C)"

Class IIa

"1. Obtaining a family history can be useful to help identify persons who may be at increased risk of stroke (Level of Evidence: A)"

Class IIb

"1. Referral for genetic counseling may be considered for patients with rare genetic causes of stroke (Level of Evidence: C)"

"2. Treatment for certain genetic conditions that pre- dispose to stroke (eg, Fabry disease and enzyme replacement therapy) might be reasonable but has not been shown to reduce risk of stroke, and its effectiveness is unknown (Level of Evidence: C)"

"3. Noninvasive screening for unruptured intracranial aneurysms in patients with ADPKD and ≥1 relatives with ADPKD and SAH or intracranial aneurysm may be considered(Level of Evidence: C)"

"4. Noninvasive screening for unruptured intracranial aneurysms in patients with ≥2 first-degree relatives with SAH or intracranial aneurysms might be reasonable (Level of Evidence: C)"

"5. Noninvasive screening for unruptured intracranial aneurysms in patients with cervical fibromuscular dysplasia may be considered(Level of Evidence: C)"

"6. harmacogenetic dosing of vitamin K antagonists may be considered when therapy is initiated(Level of Evidence: C)"

References

Template:WS Template:WH